Dr. François Chast, chief of pharmacology at the Hotel-Dieu and professor at the Faculty of Pharmacy Paris-Descartes, considers the publication Afssaps the list of 77 drugs under surveillance. Read Article
What are your feelings about publishing the list of drugs under enhanced?
She arrives in a particular context. The first case Mediator. And then a context of "We were wrong does not tell us everything." And then, suddenly the authorities feel obliged to make a kind of pharmacological happening, putting on the public information that is already known, and even professionals the public who would spontaneously on the site Afssaps.
But I think that fear is never a good adviser. And there was a panic about these safety issues. Public authorities have meant: "We made mistakes, perhaps mistakes with the Mediator, but we're working hard."
What are the risks of this publication?
Confusion. These drugs have nothing to do with each other. Some are very common and OTC, long time. Other diseases affect very rare, for which the physician is usually a specialist, who does not suffer the pressure of his patients. In the case of multiple myeloma for example, which is fatal within months if untreated, yes, we take the risk of using a drug that has a profit.
In Case Mediator, we had a drug that served no purpose except to be an appetite suppressant that does not say his name and for which the manufacturer has misled patients, prescribers and health authorities.
Among the common drugs, Di-antalvic, will be withdrawn from sale in March 2011, a lot of noise.
is a drug that we ... Read more on LEXPRESS.fr
http://www.lexpress.fr/actualite/sciences/sante/la-pharmacie-n-est-pas-une-confiserie_959546.html xtor # = AL 447
0 comments:
Post a Comment